BTX 1801 trial early Q2 2020, page-30

The Australian site data should provide enough evidence to satisfy FDA... time will tell ,,, but you can be sure the FDA will be stepping UP efforts to fastrack processing of ,,, well everything,,, all eyes on organisations like the FDA at present ,
These are uncertain times but BOT was never a 1 trick pony , luckily BOT had more than one bullet , some Biotechs go to the wall on a single binary outcome, BOT are diverse across Dermal CBD Treatments... we can only but rely on Management to pick up the mantle and make the most of a poor situation ,,, plus we still have a solid cash position.... in fact BOT has more cash than some ASX Biotechs have MC.